Commercial Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch BioPharma DiveA strong performance from Mounjaro overseas boosted Lilly s results, and the company raised its guidance for the year for both profit and revenue.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) BioPharma Dive A strong performance from Mounjaro overseas boosted Lilly s results, and the company raised its guidance for the year for both profit and revenue. Read full story Post navigation Previous: Lilly clocks 56% revenue increase in Q1 but declining prices stunt growthNext: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026